Nuwiq is approved by the Food and Drug Administration (FDA) to treat and prevent bleeding episodes in children and adults with hemophilia A (congenital factor VIII deficiency). The technical name of Nuwiq is Human coagulation factor VIII (rDNA), simoctocog alfa.
Nuwiq is a clotting factor. Clotting factors work by supplying proteins missing in people with bleeding disorders.
How do I take it?
Prescribing information states that Nuwiq is given as an intravenous injection.
Nuwiq comes as a powder that must be reconstituted before injection.
The FDA-approved label for Nuwiq does not list common side effects. Less commonly, Nuwiq may cause headache, dry mouth, vertigo, pins-and-needles sensations, back pain, and pain at injection site.
Rare but serious side effects listed for Nuwiq include life-threatening hypersensitivity reactions, complications involving the catheter of the central venous access device (CVAD), and the development of inhibitors.
For more details about this treatment, visit:
Treatment of Hemophilia – Hemophilia Federation of America